Stryker Co. (NYSE:SYK) Receives Consensus Rating of "Moderate Buy" from Analysts

Stryker Co. (NYSE:SYK - Get Free Report) has earned an average rating of "Moderate Buy" from the nineteen research firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $423.05.

SYK has been the topic of a number of recent research reports. Citigroup reiterated a "buy" rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Barclays raised their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th.

Stryker Stock Performance

SYK stock traded up $1.63 during midday trading on Tuesday, reaching $350.02. 1,767,159 shares of the company were exchanged, compared to its average volume of 1,358,209. The firm has a market capitalization of $133.60 billion, a price-to-earnings ratio of 45.11, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The business has a 50-day moving average price of $375.54 and a two-hundred day moving average price of $373.55. Stryker has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 earnings per share. Equities research analysts forecast that Stryker will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.96%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the fourth quarter valued at approximately $25,000. Capital A Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at $26,000. Dunhill Financial LLC increased its position in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. raised its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after buying an additional 68 shares during the last quarter. Finally, Centricity Wealth Management LLC acquired a new position in Stryker in the fourth quarter valued at $30,000. Institutional investors own 77.09% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.